Facebook Twitter LinkedIn YouTube Instagram

To navigate the following site navigation expect to utilize the tab key to move through items sequentially. The spacebar or enter keys can be utilized to interact with items that open sub-navigation.

The next tab will be the search box toggle. Hit enter to open the search, focus will automatically shift to the search bar. Type a letter into the search input and suggested results will appear.

Drug

Macitentan (OPSUMIT®)

Status:

Phase 2

Condition:

Systemic Sclerosis ILD

Intervention Type:

Oral Drug

Funder Type:

Organization | University

Drug Detail

OPSUMIT^® (macitentan) is an endothelin receptor antagonist approved for the treatment of pulmonary arterial hypertension.

Study Purpose

Patients with interstitial lung disease (ILD) and scleroderma who develop pulmonary hypertension (PH) do not fit well into the current classification system and treatments for pulmonary hypertension. This study aims to better understand patients with ILD-PH and scleroderma and to determine if treatment with Opsumit (aka Macitentan) is beneficial.

This drug has no clinical trials actively recruiting patients at this time.